keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal meningitis

keyword
https://www.readbyqxmd.com/read/29325425/meningitis-vaccination-knowledge-and-awareness-among-ymsm-in-chicago
#1
Gregory Phillips, Amy K Johnson, Christian N Adames, Brian Mustanski
Serogroup C invasive meningococcal disease (IMD) outbreaks in men who have sex with men (MSM) have been occurring with greater frequency in urban areas across the United States. An effective vaccine for IMD is available and is recommended for MSM in outbreak settings. Particular subgroups of MSM have been disproportionately represented in outbreaks, specifically young, Black, and HIV-positive MSM. As little is known about the knowledge, awareness, and vaccination status of young MSM, we sought to describe this and explore racial/ethnic differences...
January 1, 2018: Health Education & Behavior: the Official Publication of the Society for Public Health Education
https://www.readbyqxmd.com/read/29290234/bacterial-meningitis-antibiotic-treatment
#2
R Cohen, J Raymond, L Hees, D Pinquier, E Grimprel, C Levy
The implementation of pneumococal conjugate vaccines (PCVs) 7 then 13 valent (Prevenar13®) in 2010-2011 has significantly changed the profile of pneumococcal meningitis. Since 3 years, the National Pediatric Meningitis Network of the Pediatric Infectious Disease Group (GPIP) and the National Reference Centre of Pneumococci have reported no cases of meningitis due to pneumococcus resistant to third-generation cephalosporins (3GC): cefotaxime or ceftriaxone. In the light of these new data, vancomycin should no longer be prescribed at the initial phase of pneumococcal meningitis treatment (confirmed or only suspected) and this antibiotic should only be added when 3GC minimum inhibitory concentration of the strain isolated is greater than 0...
December 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/29274002/a-periodic-disease-transmission-model-with-asymptomatic-carriage-and-latency-periods
#3
Isam Al-Darabsah, Yuan Yuan
In this paper, the global dynamics of a periodic disease transmission model with two delays in incubation and asymptomatic carriage periods is investigated. We first derive the model system with a general nonlinear incidence rate function by stage-structure. Then, we identify the basic reproduction ratio [Formula: see text] for the model and present numerical algorithm to calculate it. We obtain the global attractivity of the disease-free state when [Formula: see text] and discuss the disease persistence when [Formula: see text]...
December 22, 2017: Journal of Mathematical Biology
https://www.readbyqxmd.com/read/29240724/large-outbreak-of-neisseria-meningitidis-serogroup-c-nigeria-december-2016-june-2017
#4
Chimeremma Nnadi, John Oladejo, Sebastian Yennan, Adesola Ogunleye, Chidinma Agbai, Lawal Bakare, Mohammed Abdulaziz, Amina Mohammed, Mary Stephens, Kyadindi Sumaili, Olivier Ronveaux, Helen Maguire, Debra Karch, Mahmood Dalhat, Martin Antonio, Andre Bita, Ifeanyi Okudo, Patrick Nguku, Ryan Novak, Omotayo Bolu, Faisal Shuaib, Chikwe Ihekweazu
On February 16, 2017, the Ministry of Health in Zamfara State, in northwestern Nigeria, notified the Nigeria Centre for Disease Control (NCDC) of an increased number of suspected cerebrospinal meningitis (meningitis) cases reported from four local government areas (LGAs). Meningitis cases were subsequently also reported from Katsina, Kebbi, Niger, and Sokoto states, all of which share borders with Zamfara State, and from Yobe State in northeastern Nigeria. On April 3, 2017, NCDC activated an Emergency Operations Center (EOC) to coordinate rapid development and implementation of a national meningitis emergency outbreak response plan...
December 15, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29228283/interaction-of-neisseria-meningitidis-group-x-n-acetylglucosamine-1-phosphotransferase-with-its-donor-substrate
#5
Shonoi A Ming, Ebony Cottman-Thomas, Natalee C Black, Yi Chen, Vamsee Veeramachineni, Dwight C Peterson, Xi Chen, Lauren M Tedaldi, Gerd K Wagner, Chao Cai, Robert J Linhardt, Willie F Vann
Neisseria meningitidis Group X is an emerging cause of bacterial meningitis in the Sub-Saharan Africa. The capsular polysaccharide of Group X is a homopolymer of N-acetylglucosamine α(1-4) phosphate and is a vaccine target for prevention of disease associated with this meningococcal serogroup. We have demonstrated previously that the formation of the polymer is catalyzed by a phosphotransferase which transfers N- acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to the 4- hydroxyl of the N-acetylglucosamine on the non-reducing end of the growing chain...
December 8, 2017: Glycobiology
https://www.readbyqxmd.com/read/29211624/vaccine-prevention-of-meningococcal-disease-in-africa-major-advances-remaining-challenges
#6
Mustapha M Mustapha, Lee H Harrison
Africa historically has had the highest incidence of meningococcal disease with high endemic rates and periodic epidemics. The meningitis belt, a region of sub-Saharan Africa extending from Senegal to Ethiopia, has experienced large, devastating epidemics. However, dramatic shifts in the epidemiology of meningococcal disease have occurred recently. For instance, meningococcal capsular group A (NmA) epidemics in the meningitis belt have essentially been eliminated by use of conjugate vaccine. However, NmW epidemics have emerged and spread across the continent since 2000; NmX epidemics have occurred sporadically, and NmC recently emerged in Nigeria and Niger...
December 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29203096/meningococcal-disease-a-clinical-and-epidemiological-review
#7
REVIEW
Rodrigo Siqueira Batista, Andréia Patrícia Gomes, Jorge Luiz Dutra Gazineo, Paulo Sérgio Balbino Miguel, Luiz Alberto Santana, Lisa Oliveira, Mauro Geller
Meningococcal disease is the acute infection caused by Neisseria meningitidis, which has humans as the only natural host. The disease is widespread around the globe and is known for its epidemical potential and high rates of lethality and morbidity. The highest number of cases of the disease is registered in the semi-arid regions of sub-Saharan Africa. In Brazil, it is endemic with occasional outbreaks, epidemics and sporadic cases occurring throughout the year, especially in the winter. The major epidemics of the disease occurred in Brazil in the 70's caused by serogroups A and C...
November 2017: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/29197599/meningococcal-carriage-within-households-in-the-african-meningitis-belt-a-longitudinal-pilot-study
#8
Nicole E Basta, Abdoulaye Berthe, Mahamadou Keita, Uma Onwuchekwa, Boubou Tamboura, Awa Traore, Musa Hassan-King, Olivier Manigart, Maria Nascimento, James M Stuart, Caroline Trotter, Jayne Blake, Anthony D Carr, Stephen J Gray, Lynne S Newbold, Yangqing Deng, Julian Wolfson, M Elizabeth Halloran, Brian Greenwood, Ray Borrow, Samba O Sow
OBJECTIVES: Carriers of Neisseria meningitidis are a key source of transmission. In the African meningitis belt, where risk of meningococcal disease is highest, a greater understanding of meningococcal carriage dynamics is needed. METHODS: We randomly selected an age-stratified sample of 400 residents from 116 households in Bamako, Mali, and collected pharyngeal swabs in May 2010. A month later, we enrolled all 202 residents of 20 of these households (6 with known carriers) and collected swabs monthly for 6 months prior to MenAfriVac vaccine introduction and returned 10 months later to collect swabs monthly for 3 months...
November 29, 2017: Journal of Infection
https://www.readbyqxmd.com/read/29194010/impact-of-serogroup-a-meningococcal-conjugate-vaccine-for-africa
#9
James M Stuart
The introduction of a serogroup A meningococcal conjugate vaccine in the African meningitis belt has been a remarkable success. Meningitis due to the serogroup A meningococcus, previously responsible for most epidemics, has fallen by 99% in vaccinated countries. Success must, however, not distract from the continuing burden of meningitis in this region of Africa. The number of all meningitis epidemics at health district level has fallen by 60% following vaccination, but epidemics due to other meningococcal serogroups continue and may be increasing...
December 1, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29187601/efficient-solid-phase-synthesis-of-meningococcal-capsular-oligosaccharides-enables-simple-and-fast-chemoenzymatic-vaccine-production
#10
Timm Fiebig, Christa Litschko, Friedrich Freiberger, Andrea Bethe, Monika Berger, Rita Gerardy-Schahn
Neisseria meningitidis serogroups A (NmA) and X (NmX) are among the leading causes of bacterial meningitis in the African meningitis belt. Glycoconjugate vaccines, consisting of an antigenic carrier protein coupled to the capsular polysaccharide of the bacterial pathogen, are the most effective strategy for prevention of meningococcal disease. However, the distribution of effective glycoconjugate vaccines in this region is limited by high cost of cultivating pathogens and purification of their capsular polysaccharides...
November 29, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29176349/epidemiology-of-community-acquired-bacterial-meningitis
#11
Matthijs C Brouwer, Diederik van de Beek
PURPOSE OF REVIEW: The epidemiology of bacterial meningitis has been dynamic in the past 30 years following introduction of conjugated vaccines against Haemophilus influenzae type B, Streptococcus pneumoniae and Neisseria meningitidis. The purpose of this review is to describe recent developments in bacterial meningitis epidemiology. RECENT FINDINGS: The incidence of bacterial meningitis in Western countries (Finland, Netherlands, and the United States) gradually declined by 3-4% per year to 0...
February 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29170349/52%C3%A2-loop-mediated-isothermal-amplification-pcr-lamp-for-the-rapid-identification-of-invasive-meningococcal-disease-in-the-emergency-department
#12
Thomas Waterfield, Bethany Patenall, James McKenna, Derek Fairley
BACKGROUND: Despite successful vaccination programmes meningococcal disease (MD) remains the leading infectious cause of septicaemia and death in children in the UK and Ireland.1,2 The early diagnosis of MD significantly improves outcomes with reduced morbidity and mortality.1,2 The early stages of MD are often indistinguishable from a simple viral illness making an early positive diagnosis of MD difficult.1 Hibergene have developed a commercially available bedside Loop-mediated isothermal AMPlification PCR (LAMP-MD) test that is a highly sensitive 0...
December 2017: Emergency Medicine Journal: EMJ
https://www.readbyqxmd.com/read/29152576/meningococcal-antigen-typing-system-mats-based-neisseria-meningitidis-serogroup-b-coverage-prediction-for-the-menb-4c-vaccine-in-the-united-states
#13
Gowrisankar Rajam, Maria Stella, Ellie Kim, Simon Paulos, Giuseppe Boccadifuoco, Laura Serino, George Carlone, Duccio Medini
Neisseria meningitidis is the most common cause of bacterial meningitis in children and young adults worldwide. A 4-component vaccine against N. meningitidis serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A (NadA), and PorA-containing outer membrane vesicles was recently approved for use in the United States and other countries worldwide. Because the public health impact of MenB-4C in the United States is unclear, we used the meningococcal antigen typing system (MATS) to assess the strain coverage in a panel of strains representative of serogroup B (NmB) disease in the United States...
November 2017: MSphere
https://www.readbyqxmd.com/read/29116892/lessons-from-the-meningitis-vaccine-project
#14
F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, Marie-Pierre Preziosi
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conjugate vaccine, MenAfriVac(®), in sub-Saharan Africa. The vaccine was well received, and from 2010 to 2016, over 260 million Africans have received a dose of the vaccine in campaigns largely directed at 1-29-year olds. The public health impact has been dramatic with the elimination of Group A meningococcal infections wherever the vaccine has been used at public health scale...
November 8, 2017: Viral Immunology
https://www.readbyqxmd.com/read/29099305/peripheral-blood-vessels-are-a-niche-for-blood-borne-meningococci
#15
Elena Capel, Jean-Philippe Barnier, Aldert L Zomer, Christine Bole-Feysot, Thomas Nussbaumer, Anne Jamet, Hervé Lécuyer, Daniel Euphrasie, Zoé Virion, Eric Frapy, Philippe Pélissier, Olivier Join-Lambert, Thomas Rattei, Sandrine Bourdoulous, Xavier Nassif, Mathieu Coureuil
Neisseria meningitidis is the causative agent of cerebrospinal meningitis and that of a rapidly progressing fatal septic shock known as purpura fulminans. Meningococcemia is characterized by bacterial adhesion to human endothelial cells of the microvessels. Host specificity has hampered studies on the role of blood vessels colonization in N. meningitidis associated pathogenesis. In this work, using a humanized model of SCID mice allowing the study of bacterial adhesion to human cells in an in vivo context we demonstrate that meningococcal colonization of human blood vessels is a prerequisite to the establishment of sepsis and lethality...
November 3, 2017: Virulence
https://www.readbyqxmd.com/read/29095907/bacterial-meningitis-epidemiology-and-return-of-neisseria-meningitidis-serogroup-a-cases-in-burkina-faso-in-the-five-years-following-menafrivac-mass-vaccination-campaign
#16
Alpha Oumar Diallo, Heidi M Soeters, Issaka Yameogo, Guetawendé Sawadogo, Flavien Aké, Clément Lingani, Xin Wang, Andre Bita, Amadou Fall, Lassana Sangaré, Rasmata Ouédraogo-Traoré, Isaïe Medah, Brice Bicaba, Ryan T Novak
BACKGROUND: Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal serogroup A conjugate vaccine (MACV) campaign. We analyzed nationwide meningitis surveillance data from Burkina Faso for the 5 years following MACV introduction. METHODS: We examined Burkina Faso's aggregate reporting and national laboratory-confirmed case-based meningitis surveillance data from 2011-2015...
2017: PloS One
https://www.readbyqxmd.com/read/29068749/combined-effect-of-pcv10-and-meningococcal-c-conjugate-vaccination-on-meningitis-mortality-among-children-under-five-years-of-age-in-brazil
#17
Ana Luiza Bierrenbach, Ruth Minamisava, Airlane Pereira Alencar, Gizelton Pereira Alencar, Ana Lucia Andrade
The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in the Brazilian National Immunization Program in March 2010, scheduled at 2, 4, and 6 months, with a booster at 12-15 months of age. The meningococcal C conjugate vaccine (MCC) was introduced in November 2010, scheduled at 3 and 5 months, with a booster dose at 12-15 months of age and no catch-up for older age groups. In this interrupted time-series analysis study, we used Brazilian mortality data from 2005 to 2015 for children under five years of age (excluding data from the state of Bahia) to assess the combined impact of these vaccines on the overall burden of meningitis mortality among children aged 0-23 months and 2-4 years, as defined using meningitis and meningococcemia specific International Classification of Diseases - tenth revision codes...
October 25, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29064356/expansion-of-vaccination-services-and-strengthening-vaccine-preventable-diseases-surveillance-in-haiti-2010-2016
#18
Rania A Tohme, Jeannot Francois, Kathleen F Cavallaro, Gilson Paluku, Idrissa Yalcouye, Ernsley Jackson, Tracie Wright, Paul Adrien, Mark A Katz, Terri B Hyde, Pape Faye, Francine Kimanuka, Vance Dietz, John Vertefeuille, David Lowrance, Benjamin Dahl, Roopal Patel
Following the 2010 earthquake, Haiti was at heightened risk for vaccine-preventable diseases (VPDs) outbreaks due to the exacerbation of long-standing gaps in the vaccination program and subsequent risk of VPD importation from other countries. Therefore, partners supported the Haitian Ministry of Health and Population to improve vaccination services and VPD surveillance. During 2010-2016, three polio, measles, and rubella vaccination campaigns were implemented, achieving a coverage > 90% among children and maintaining Haiti free of those VPDs...
October 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29048988/developmental-strategy-for-a-new-group-a-meningococcalconjugate-vaccine-menafrivac-r
#19
Prasad S Kulkarni, Suresh S Jadhav, F Marc LaForce
Until recently, periodic Group A meningococcal meningitis outbreaks were a major public health problem in the sub-Saharan Africa. In 2001, the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and PATH, a Seattle-based NGO, and the Serum Institute of India Pvt Ltd (SIIPL) initiated discussions aimed at establishing a collaborationto develop a Group A meningococcal conjugate vaccine for this unmet medical need. Over the next 8 years the partnership made countless strategic decisions about product characteristics, raw materials, potential target populations, geographic prioritization and affordability of the vaccine to name a few...
October 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29037978/expected-immunizations-and-health-protection-for-hajj-and-umrah-2018-an-overview
#20
REVIEW
Jaffar A Al-Tawfiq, Philippe Gautret, Ziad A Memish
BACKGROUND: The annual Hajj and Umrah are one of the largest recurring religious mass gatherings across the globe drawing pilgrims from more than 185 countries. The living circumstances and activities of the pilgrims may create an environment for the occurrence and spread of communicable diseases. Each year, the Health authority of the Kingdom of Saudi Arabia, in coordination with international health authorities, updates health requirements for pilgrims. The Hajj for 2017 took place from August 24 to September 5, 2017...
October 14, 2017: Travel Medicine and Infectious Disease
keyword
keyword
90021
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"